Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Aug - We hereby submit Newspaper publication. Kindly take the same on your records.
Source: Bse
Ambalal Sarabhai Enterprises Limited (AMBALALSA)
Small CapPharma stocks · Small cap · NSE
Ambalal Sarabhai Enterprises Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result12 Aug, 04:54 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
62BullishSMA20 -7.7% / mo · MACD − · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 36
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
AMBALALSAD candles · FIT view+14.7%Latest close ₹36.65 on 2026-10-21
Daily history is available from 2026-04-20; the requested 1Y window is partially covered.
Bar
-6.0%
RSI
38
MACD hist
-0.15
52W pos
33%
2026-10-21O ₹38.98H ₹38.98L ₹36.59C ₹36.65Vol 32,710 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
AMBALALSANifty PharmaNifty 500
- AMBALALSA
- +14.6%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +21.1 pp
Chart stats
21 Oct 2026- From 52W high
- -26.7%
- 52W range position
- 33%
- ATR (14)
- 5.3%
- Volume vs 20D
- 0.76x
- Avg traded value
- ₹0.2 Cr
- 20D price channel
- ₹36.5 - ₹42.9
₹50
₹30.2 - ₹50
₹1.9
Latest completed session
20-session average
44.8% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · WATCHLIST40
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad5
Revenue +8.0% · PAT -51.6% YoY
Technical
Bullish62
Price trend and sector-relative-strength timing.
Valuation
Legacy model+33.7%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence73
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 5/100PAT -52% YoY · Rev +8% YoY · margin expansion
Filed 12 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹43.6 Cr | +8.0% | -33.5% |
| EBITDA | ₹4.6 Cr | +211.6% | -20.2% |
| Operating margin | 10.4% | +683 bps | +175 bps |
| PAT | ₹4 Cr | -51.6% | -38.8% |
| PAT margin | 9.1% | -1124 bps | -79 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 20.40
- P/B
- 1.84
- EV/EBITDA
- 18.32
- Market Cap
- 291.00Cr
Profitability
- ROE
- 12.40%
- ROCE
- 11.70%
- ROA
- 5.00%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 4.00%
- EPS 5Y
- 10.00%
- Revenue 3Y
- 6.00%
- EPS 3Y
- 17.00%
Balance Sheet
- Debt/Equity
- 0.36
- Interest Coverage
- 3.75×
- Altman Z
- 2.97
- Book Value
- 20.70
Cash Flow
- FCF Yield
- 1.03%
- FCF Positive Y
- 10/5
- OCF
- 13.00 Cr
- EPS TTM
- 1.77
Shareholding
- Promoter Hold
- 31.36%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 55%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 43.6-33.5% vs prev
Net Profit
₹ CrLatest: 4.0-38.8% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend unclear. RSI 38.
- SMA20 falling (~8.3% over last month) — short-term momentum negative.
- RSI(14) at 38 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 27% off 52W high · 22% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
79
RS percentile
Insufficient history
1M return
-5.4%
3M return
+14.6%
6M return
+15.3%
1Y return
-
RS 1D
0
RS 20D
-
Sector rank
#1
Industry rank
#9
Stage evidence
- At least 170 daily sessions are required for the trend-stage read.
50-DMA
price below
200-DMA
unavailable
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
128 observations
21 Oct 2026Value 118.26-3.94%
RS vs Nifty 500118
Valuation & peers
U-Score 40 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 40 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation11/30
Growth11/25
Quality4/20
Balance Sheet7/15
Cash Flow5/10
Piotroski
7/9 (+5)
Penalties
-3
Raw sum
40
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
40/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 7/9.
- Fair-value margin of safety is positive at 33.7%.
- Cash flow contributes 5/10 to the score.
Main drags
- Penalty bucket subtracts 3 points.
- Quality is weaker at 4/20; verify the latest quarterly trend.
- Valuation is weaker at 11/30; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
20.4
PB
1.8
EV/EBITDA
18.3
ROE
12.4%
ROCE
11.7%
FCF Yield
1.0%
Debt/Equity
0.4
MoS
+33.7%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
40
Previous: 41 (-1)
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+33.7%
Previous: +30.3%
Score history
12 stored score snapshots. Latest stored move: +1 points.
21 Oct 2026
v4.3-runtime-valuation
40
40
40
40
40
40
40
40
40
40
40
41
Factor attribution
Valuation
11-1
was 12
Modelled fair value
Graham Number
₹28.71
-27.6% MoS
Growth-justified P/E
31.2
Growth-justified Value
₹55.26
+33.7% MoS
PEG
1.59
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
AAREYDRUGS
Small
Aarey Drugs & Pharmaceuticals Limited
Pharmaceuticals
match 164
15
79.4
2.8%
-1817%
OVERVALUED
BALPHARMA
Small
Bal Pharma Limited
Pharmaceuticals
match 162
23
23.6
7.9%
-44%
OVERVALUED
BROOKS
Small
Brooks Laboratories Limited
Pharmaceuticals
match 162
60
12.1
22.0%
+68%
UNDERVALUED
MEDICAMEQ
Small
Medicamen Biotech Limited
Pharmaceuticals
match 162
18
38.9
4.0%
-521%
OVERVALUED
ALPA
Small
Alpa Laboratories Limited
Pharmaceuticals
match 162
32
30.6
8.4%
+40%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Ambalal Sarabhai Enterprises Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
73Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 72nd percentile of the scored universe and 63rd percentile within Pharma. Main check: results consistency is weak at 53/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
3 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
72nd percentile
overall median 67 · Pharma: 63rd pctile, median 70 · Small: 75th pctile, median 66
Evidence depth
Financial-only
3 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
68
acceptable · capital discipline
Results
53
watch · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.9%.
- ▸10 years of positive FCF.
- ▸3/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸2 latest quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Ambalal Sarabhai Enterprises Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementJul 2026
Jul 2026 · Results - Financial Results As On 31.03.2026 21 May
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Change in Management 21 May - Board approved FY26 audited results, AGM on 30 July 2026, and several director reappointments.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 13 Jul - We hereby submit newspaper publication for AGM. Kindly take the same on your records.
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 8 Jul
Source: Bse
Annual report
Reg. 34 (1) Annual Report. 7 Jul
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 24 May - We hereby submit clippings of Newspaper. Kindly take the same on your records.
Source: Bse
Announcement
Shareholders Meeting Intimation 21 May
Source: Bse
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Bse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.